Last Updated

16 Sep 2020

Evaluating the impact of COVID-19 on malaria and other infectious diseases in Uganda: Understanding comorbidities

Objectives

To understand the burden chiefly of malaria (but also of TB and HIV/AIDS) among patients with COVID-19, and to assess the clinical consequences of potential interactions.

This project will:

  • Determine the prevalence of malaria among COVID-19 patients and evaluate the risk of malaria following hospital discharge
  • Determine the level of previous exposure to malaria among patients with COVID-19
  • Document the impact of malaria on clinical outcomes of patients with COVID-19
  • Assess the potential impact of currently used antimalarial drugs (artemether-lumefantrine and dihydroartemisinin-piperaquine) on clinical outcomes among COVID-19 patients, when prescribed to treat their malaria infections
  • Document the clinical spectrum of malaria among patients with COVID-19
  • Evaluate the potential interactions between COVID-19 and other infectious diseases, including HIV/AIDS and TB
  • Describe health workers’ perspectives on the management of malaria in COVID-19 patients.

Principal Institution(s)

Principal Investigator
Rationale and Abstract

Recognizing the heavy toll that malaria and other infectious diseases have on vulnerable populations in sub-Saharan Africa, Malaria Consortium and Uganda’s Ministry of Health (MoH) will conduct a case series on COVID-19 patients — a descriptive clinical study that reports on patients with a particular condition who are receiving similar treatment. This research seeks to understand the burden chiefly of malaria (but also of TB and HIV/AIDS) among patients with COVID-19, and to assess the clinical consequences of potential interactions.


The case series will form part of the MoH’s ongoing clinical assessment and care administered to COVID-19 patients. It will be carried out at all COVID-19 treatment centres across Uganda and will include patients of all ages, and at various stages of infection, who have a confirmed diagnosis of COVID-19 according to World Health Organization (WHO) and MoH guidelines.

Study Design

Study Design: Observational - Prospective Case series

In order to achieve these objectives, Malaria Consortium will:

  • collate demographic and clinical information about patients in the study, including travel history, medical history, current symptoms and medications, and findings of clinical examinations
  • train research assistants on study procedures, including infection prevention and control
  • collect, test and analyse blood samples from patients, checking for previous exposure to malaria parasites, current malaria infection status, HIV, haematology and biochemistries
  • use qualitative methods to assess health workers’ perspectives on the management of malaria in COVID-19 patients
  • develop a report documenting the findings of the study and prepare outputs for peer review

Outcome Measures

  • Prevalence of malaria among patients with COVID-19 
  • Clinical spectrum of malaria among patients with COVID-19
  • Clinical outcomes of COVID-19 patients with malaria compared to those with no malaria
  • Clinical outcomes among COVID-19 patients prescribed currently used antimalarial drugs as per current clinical indications
  • Impact co-infections including malaria, HIV/AIDS and TB on COVID-19 outcomes 

Date

2020 Apr - 2020 Sep

Total Project Funding

$100,000

Funding Details

Project Site
<